Pfizer Pipeline



October 31, 2023

Disclaimer

- The information contained on these pages is accurate as of October 31, 2023 to the best of Pfizer's knowledge. Pfizer assumes no obligation to update this information.

- This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no guarantees with respect to pipeline products that clinical studies will be successful, that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in or implied by the forward-looking statements. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in our subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant commercial opportunities.

- Visit www.pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

Pfizer Pipeline Snapshot



Pfizer Pipeline Snapshot as of October 31, 2023

Pipeline represents progress of R&D programs as of October 31, 2023

- 8 programs advanced or are new
- 5 programs discontinued since last update
- Included are 53 NMEs, 30 additional indications

Recent Approvals

The U.S. Food and Drug Administration (FDA) granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

The FDA also approved ABRYSVO™ (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, for the prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age. The European Commission (EC) has granted marketing authorization for ABRYSVO™, to help protect both infants through maternal immunization and older adults.

The FDA approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The EC authorized the Comirnaty XBB.1.5-adapted COVID-19 vaccine for individuals 6 months of age and older.

The EC granted marketing authorization for LITFULO™ (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe alopecia areata.

The FDA approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.

The FDA approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC).

The FDA approved PENBRAYA™ (active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y), for use in individuals 10 through 25 years of age.



Pfizer Pipeline Snapshot as of August 1, 2023

Anti-Infectives

Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
aztreonam-avibactam (PF-06947387)	Beta lactam/beta lactamase inhibitor	Treatment of adult patients with cIAI, HAP/VAP, cUTI including pyelonephritis and treatment of infections due to aerobic gram-negative organisms in adult patients with limited treatment options	Phase 3	New Molecular Entity
PAXLOVID™	SARS-CoV-2 3CL protease inhibitor (oral COVID-19 treatment)	COVID-19 Infection (pediatric)	Phase 3	Product Enhancement
fosmanogepix (APX001)	Gwt1 inhibitor	Invasive Fungal Infections	Phase 2	New Molecular Entity
sisunatovir (PF-07923568)	Respiratory syncytial virus fusion inhibitor	Respiratory Syncytial Virus infection in Pediatrics and Adults (FAST TRACK – U.S.)	Phase 2	New Molecular Entity
PF-07817883	SARS-CoV-2 3CL protease inhibitor (oral COVID-19 treatment)	COVID-19 Infection (FAST TRACK – U.S.)	Phase 2	New Molecular Entity
CTB+AVP (PF-07612577)	Beta lactam/Beta lactamase inhibitor	Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis	Phase 1	New Molecular Entity

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

Inflammation and Immunology

Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
LITFULO™ (ritlecitinib)	JAK3/TEC inhibitor	Vitiligo	Phase 3	Product Enhancement
Dazukibart (PF-06823859)	interferon, beta 1, fibroblast (IFNB1) blocker	Dermatomyositis, Polymyositis (Biologic) (ORPHAN - U.S., E.U., PRIME - E.U.)	Phase 3	New Molecular Entity
fordadistrogene movaparvovec (PF-06939926)	Gene therapy, minidystrophin	Duchenne Muscular Dystrophy Ambulatory (Biologic) (FAST TRACK, RPD – U.S.; ORPHAN - U.S., E.U.)	Phase 3	New Molecular Entity
LITFULO™ (ritlecitinib)	JAK3/TEC inhibitor	Ulcerative Colitis	Phase 2	Product Enhancement
LITFULO™ (ritlecitinib)	JAK3/TEC inhibitor	Crohn's Disease	Phase 2	Product Enhancement
Dekavil[1]	IL-10	Rheumatoid Arthritis (Biologic)	Phase 2	New Molecular Entity
VELSIPITY™ (etrasimod)	S1P inhibitor	Eosinophilic Esophagitis	Phase 2	Product Enhancement
VELSIPITY™ (etrasimod)	S1P inhibitor	Alopecia Areata	Phase 2	Product Enhancement
VELSIPITY™ (etrasimod)	S1P inhibitor	Crohn's disease[2]	Phase 2	Product Enhancement
VELSIPITY™ (etrasimod)	S1P inhibitor	Atopic Dermatitis	Phase 2	Product Enhancement
PF-06835375	anti-CXCR5	Immune Thrombocytopenic Purpura (Biologic)	Phase 2	New Molecular Entity
►PF-07275315	anti-IL-4/ IL-13/ TSLP	Atopic Dermatitis (Biologic)	Phase 2	New Molecular Entity
►PF-07264660	anti-IL-4/ IL-13/ IL-33	Atopic Dermatitis (Biologic)	Phase 2	New Molecular Entity
►Dazukibart (PF-06823859)	interferon, beta 1, fibroblast (IFNB1) blocker	Lupus (Biologic)	Phase 2	Product Enhancement
PF-06835375	anti-CXCR5	Lupus (Biologic)	Phase 1	Product Enhancement
PF-07054894	CCR6 antagonist	Inflammatory Bowel Disease	Phase 1	New Molecular Entity
PF-07261271	p40/TL1a bi-specific	Inflammatory Bowel Disease (Biologic)	Phase 1	New Molecular Entity

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

1. Clinical trial conducted by Philogen S.p.A
2. Etrasimod in Crohn's disease is a Ph2/3 clinical trial

Internal Medicine (1 of 2)



Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
fidanacogene elaparvovec (PF-06838435)	Gene therapy, coagulation factor IX (F9)	Hemophilia B (Biologic) (RMAT, BREAKTHROUGH – U.S., ORPHAN - U.S., E.U.)	Registration	New Molecular Entity
NGENLA™ (somatrogon)	Human growth hormone agonist	Adult Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.)	Phase 3	Product Enhancement
marstacimab (PF-06741086)	Anti-tissue factor pathway inhibitor	Hemophilia (Biologic) (FAST TRACK – U.S.; ORPHAN - U.S., E.U.)	Phase 3	New Molecular Entity
giroctocogene fitelparvovec (PF-07055480)	Gene therapy, coagulation factor VIII (F8)	Hemophilia A (Biologic) (RMAT, FAST TRACK, ORPHAN - U.S., E.U.)	Phase 3	New Molecular Entity
Inclacumab (PF-07940370)	Anti-P-selectin inhibitor	Sickle Cell Disease (Biologic) (ORPHAN – U.S.)	Phase 3	New Molecular Entity
Oxbryta® (voxelotor)	HbS polymerization inhibitor	Sickle Cell Disease - Pediatric	Phase 3	Product Enhancement
ZAVZPRET™ (zavegepant) (oral)[1]	calcitonin gene-related peptide (CGRP) receptor antagonist	Migraine Prevention	Phase 2	Product Enhancement
ervogastat (PF-06865571)	Diacylglycerol O-Acyltransferase 2 (DGAT2) inhibitor	Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis	Phase 2	New Molecular Entity
ervogastat (PF-06865571) + clesacostat (PF-05221304)	Diacylglycerol O-Acyltransferase 2 (DGAT2) inhibitor; Acetyl CoA-Carboxylase (ACC) inhibitor	Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK – U.S.)	Phase 2	New Molecular Entity
danuglipron (PF-06882961)	Glucagon-like peptide 1 receptor (GLP-1R) agonist	Type 2 Diabetes Mellitus	Phase 2	New Molecular Entity
danuglipron (PF-06882961)	Glucagon-like peptide 1 receptor (GLP-1R) agonist	Obesity	Phase 2	Product Enhancement

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

1. Zavegepant (oral) for Migraine Prevention is a Ph2/3 clinical trial

Internal Medicine (2 of 2)

Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
ponsegromab (PF-06946860)	Growth Differentiation Factor 15 (GDF15) monoclonal antibody	Cancer Cachexia (Biologic)	Phase 2	New Molecular Entity
ponsegromab (PF-06946860)	Growth Differentiation Factor 15 (GDF15) monoclonal antibody	Heart Failure (Biologic)	Phase 2	Product Enhancement
PF-07940367 (GBT021601)	HbS polymerization inhibitor	Sickle Cell Disease (ORPHAN – U.S.)	Phase 2	New Molecular Entity
PF-07258669	Melanocortin-4 receptor (MC4R) antagonist	Malnutrition	Phase 1	New Molecular Entity
PF-07328948	Branched chain ketoacid dehydrogenase kinase (BDK) inhibitor	Heart Failure with Preserved Ejection Fraction	Phase 1	New Molecular Entity
PF-07853578	PNPLA3 modulator	Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis	Phase 1	New Molecular Entity
►PF-07293893	AMPKγ3 activator	Heart Failure	Phase 1	New Molecular Entity
►PF-06954522	Glucagon-like peptide 1 receptor (GLP-1R) agonist	Type 2 Diabetes Mellitus	Phase 1	New Molecular Entity

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

1. Zavegepant (oral) for Migraine Prevention is a Ph2/3 clinical trial

Oncology (1 of 2)



Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
►XTANDI® (enzalutamide)	Androgen receptor inhibitor	Non-metastatic High-Risk Castration Sensitive Prostate Cancer (PRIORITY REVIEW – U.S.)	Registration	Product Enhancement
IBRANCE® (palbociclib)	CDK 4,6 kinase inhibitor	ER+/HER2+ Metastatic Breast Cancer (PATINA)	Phase 3	Product Enhancement
sasanlimab (PF-06801591) + Bacillus Calmette-Guerin (BCG)	Anti-PD-1	Non-Muscle-Invasive Bladder Cancer (Biologic)	Phase 3	New Molecular Entity
TALZENNA® (talazoparib)	PARP inhibitor	Combo w/ XTANDI® (enzalutamide) for DNA Damage Repair (DDR)-deficient Metastatic Castration Sensitive Prostate Cancer	Phase 3	Product Enhancement
BRAFTOVI® (encorafenib) + ERBITUX® (cetuximab) + chemotherapy	*BRAF* kinase inhibitor and anti-EGFR	1st line BRAF-mutant Metastatic Colorectal Cancer	Phase 3	Product Enhancement
BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) + KEYTRUDA® (pembrolizumab)	*BRAF* kinase inhibitor and MEK inhibitor and anti-PD-1	BRAF-mutant Metastatic or Unresectable Locally Advanced Melanoma	Phase 3	Product Enhancement
ELREXFIO™ (elranatamab-bcmm)	BCMA-CD3 bispecific antibody	Multiple Myeloma Double-Class Exposed (Biologic)	Phase 3	Product Enhancement
ELREXFIO™ (elranatamab-bcmm)	BCMA-CD3 bispecific antibody	Newly Diagnosed Multiple Myeloma Post-Transplant Maintenance (Biologic)	Phase 3	Product Enhancement
ELREXFIO™ (elranatamab-bcmm)	BCMA-CD3 bispecific antibody	Newly Diagnosed Multiple Myeloma Transplant-Ineligible (Biologic)	Phase 3	Product Enhancement
vepdegestrant (ARV-471)	ER-targeting PROTAC® protein degrader	ER+/HER2- Metastatic Breast Cancer[1]	Phase 3	New Molecular Entity

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

- ERBITUX® is a registered trademark of ImClone LLC
- KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp.
- PROTAC® is a registered U.S. trademark of Arvinas.

1. Vepdegestrant is being co-developed with Arvinas

Oncology (2 of 2)

Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
IBRANCE® + vepdegestrant (ARV-471)	CDK 4,6 kinase inhibitor ER-targeting PROTAC® protein degrader	ER+/HER2- Metastatic Breast Cancer[1]	Phase 2	New Molecular Entity
vepdegestrant (ARV-471)	ER-targeting PROTAC® protein degrader	ER+/HER2- Early Breast Cancer[1]	Phase 2	Product Enhancement
maplirpacept (TTI-622)	CD47-SIRPα fusion protein	Hematological Malignancies (Biologic)	Phase 2	New Molecular Entity
PF-06821497 + enzalutamide	EZH2 inhibitor	Prostate Cancer	Phase 2	New Molecular Entity
PF-07220060	CDK4 inhibitor	Breast Cancer Metastatic	Phase 2	New Molecular Entity
PF-07062119	GUCY2c CD3 bispecific antibody	Advanced/Metastatic Gastrointestinal Cancer (Biologic)	Phase 1	New Molecular Entity
PF-06940434	Integrin alpha-V/beta-8 antagonist	Solid Tumors (Biologic)	Phase 1	New Molecular Entity
PF-07104091	CDK2 inhibitor	Breast Cancer Metastatic	Phase 1	New Molecular Entity
PF-07248144	KAT6 epigenetic modifier	Breast Cancer Metastatic	Phase 1	New Molecular Entity
PF-07284892[2]	SHP2 tyrosine phosphatase inhibitor	Cancer	Phase 1	New Molecular Entity
PF-07260437	B7H4-CD3 bispecific	Breast Cancer Metastatic (Biologic)	Phase 1	New Molecular Entity
PF-07104091 + PF-07220060	CDK2 + CDK4 inhibitors	Breast Cancer Metastatic	Phase 1	New Molecular Entity
PF-07799933 BRAF Class 2	BRAF Class 1 and Class 2 inhibitor	Cancer	Phase 1	New Molecular Entity
PF-07104091	CDK2 inhibitor	Ovarian Cancer	Phase 1	Product Enhancement
PF-07220060 + enzalutamide	CDK4 inhibitor	Prostate Cancer	Phase 1	Product Enhancement
PF-07799544	MEK brain penetrant inhibitor	Solid Tumors	Phase 1	New Molecular Entity
PF-07248144 + PF-07220060	KAT6 epigenetic modifier + CDK4 inh	Breast Cancer Metastatic	Phase 1	New Molecular Entity

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

1. Vepdegestrant is being co-developed with Arvinas
2. PF-07284892 is being tested as a single agent and in combination therapy

- PROTAC® is a registered U.S. trademark of Arvinas

Rare Diseases/Non-Malignant Hematology

Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
VTX-801	Recombinant AAV (rAAV) vector-based gene therapy	Wilson Disease (Biologic) [1]	Phase 1	New Molecular Entity

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

1. Clinical trial conducted by Vivet Therapeutics

Vaccines



Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
COVID-19 Vaccine	Prophylactic mRNA vaccine	COVID-19 Infection (in collaboration with BioNTech) (U.S. – 5 - 11 years of age)	Registration	Product Enhancement
COVID-19 Vaccine	Prophylactic mRNA vaccine	COVID-19 Infection (in collaboration with BioNTech) (U.S. – children 6 months to 4 years of age)	Registration	Product Enhancement
PF-06425090	Prophylactic vaccine	Primary *Clostridioides difficile* Infection (FAST TRACK – U.S.)	Phase 3	New Molecular Entity
PF-07307405	Prophylactic vaccine	Lyme Disease (FAST TRACK – U.S.)	Phase 3	New Molecular Entity
PF-07252220	Prophylactic mRNA vaccine	Influenza (adults)	Phase 3	New Molecular Entity
COVID-19 Vaccine	Prophylactic mRNA vaccine	COVID-19 Infection (in collaboration with BioNTech) (U.S. – 6 months through 11 years of age)	Phase 3	Product Enhancement
PF-06760805	Prophylactic vaccine	Invasive Group B Streptococcus Infection (maternal) (BREAKTHROUGH, FAST TRACK – U.S., PRIME - EU)	Phase 2	New Molecular Entity
PF-07960613	Prophylactic vaccine	Combination Respiratory Syncytial Virus & modRNA COVID-19	Phase 2	New Molecular Entity
►PF-07926307	Prophylactic mRNA vaccine	Combination COVID-19 & Influenza (in collaboration with BioNTech) (FAST TRACK – U.S.)	Phase 2	New Molecular Entity
PF-07845104	Prophylactic saRNA vaccine	Influenza (adults)	Phase 1	New Molecular Entity
PF-07941314	Prophylactic vaccine	Combination Respiratory Syncytial Virus & Influenza (adults)	Phase 1	New Molecular Entity
PF-07911145	Prophylactic mRNA vaccine	Varicella (in collaboration with BioNTech)	Phase 1	New Molecular Entity
►ABRYSVO™ (PF-06928316)	Prophylactic vaccine	Respiratory Syncytial Virus Infection (pediatric)	Phase 1	Product Enhancement

►Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com
Regulatory Designations – See Definitions in Backup

Programs Discontinued from Development since August 1, 2023

Compound Name	Mechanism of Action	Indication	Phase of Development	Submission Type
PF-06730512	Fusion protein containing SLIT ligand portion of ROBO2 receptor	Focal Segmental Glomerulosclerosis (FSGS) (Biologic)	Phase 2	New Molecular Entity
PF-07038124	Topical PDE4 inhibitor	Atopic Dermatitis and Psoriasis	Phase 2	New Molecular Entity
PF-06647020	PTK7 targeted cytotoxicity	NSCLC (Biologic)	Phase 1	New Molecular Entity
PF-07257876	CD47xPDL1 bispecific	NSCLC (Biologic)	Phase 1	New Molecular Entity
PF-07265028	HPK1 inhibitor	Solid Tumors	Phase 1	New Molecular Entity

Appendix

Regulatory Designations

- **Fast Track** (U.S.) is a designation available to a product if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. This designation is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions so that an approved product can reach the market expeditiously. More information about the qualifying criteria and features of the Fast Track program can be found on the FDA's website.
- **Breakthrough Designation** (U.S.) may be granted to a drug (alone or in combination with 1 or more other drugs) intended to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. A drug that receives breakthrough designation is eligible for all fast-track designation features and an FDA commitment to work closely with the sponsor to ensure an efficient drug development program. More information about the qualifying criteria and features of the Breakthrough program can be found on the FDA's website.
- **Orphan Drug** (U.S.) - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention, or treatment of rare diseases/disorders that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but where it is unlikely that expected sales of the product would cover the sponsor's investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the FDA's website.
- **Regenerative Medicine Advanced Therapy (RMAT)** (U.S.) is a designation that is granted to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, for which preliminary clinical evidence indicates that the medicine has the potential to address an unmet medical need. The RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with FDA.
- **Rare Pediatric Disease (RPD)** (U.S.) designation may be granted to a drug intended to treat a rare pediatric disease that is serious or life-threatening in which the serious or life-threatening manifestations primarily affect patients from birth to 18 years, including neonates, infants, children, and adolescents.
- **Priority Review** (U.S.) A U.S. drug application will receive a priority review designation if it is for a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. A priority designation is intended to direct overall attention and resources to the evaluation of such applications. A priority review designation means that FDA's goal is to act on the marketing application within 6 months of receipt (compared with 10 months under standard review). More information about the qualifying criteria and features of a priority review designation can be found on the FDA's website.
- **Orphan Drug** (E.U.) - Orphan drug status may be granted to drugs and biologics that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than 5 in 10,000 persons in the European Union at the time of submission of the designation application, or that affect more than 5 in 10,000 persons but where it is unlikely that expected sales of the product would cover the investment in its development. More information about the qualifying criteria, features, and incentives involved in an orphan drug designation can be found on the EMA's website.
- **PRIME** (E.U.) **-** The PRIME scheme is applicable to products under development which are innovative and yet to be placed on the EU market. The scheme aims to support medicinal products of major public health interest and from the viewpoint of therapeutic innovation. Medicines eligible for PRIME must address an unmet medical need, i.e., for which there exists no satisfactory method of diagnosis, prevention or treatment in the Community or, if such a method exists, in relation to which the medicinal product concerned will be of major therapeutic advantage to those affected. A product eligible for PRIME should demonstrate the potential to address, to a significant extent, the unmet medical need, for example by introducing new methods of therapy or improving existing ones. Data available to support the request for eligibility should support the claim to address the unmet medical need through a clinically meaningful improvement of efficacy, such as having an impact on the prevention, onset or duration of the condition, or improving the morbidity or mortality of the disease. EMA will provide early and enhanced support to optimize the development of eligible medicines. Products granted PRIME support are anticipated to benefit from the Accelerated Assessment procedure. More information about the qualifying criteria and features of PRIME and Accelerated Assessment can be found on the EMA's website.